-transparent.png){kind=logo}
The effects of bucillamine, a new antirheumatic drug, on type II collagen induced arthritis in rats was examined. Bucillamine inhibited hindpaw swelling in a dose dependent manner. The histopathological study indicated that bucillamine inhibited the proliferation of synovial lining cells. The anti-type II collagen antibody level was also decreased by the treatment with bucillamine. D-penicillamine, on the other hand, showed no beneficial effects on arthritis except for inhibiting new bone formation. Our findings suggest that bucillamine has beneficial effects on type II collagen induced arthritis in rats and that its mechanism of action is different from those of D-penicillamine.
M Hayashi, and
K Matsunaga, and
A Okahara, and
S Mita
August 2010,
Modern rheumatology,
M Hayashi, and
K Matsunaga, and
A Okahara, and
S Mita
January 1988,
Methods in enzymology,
M Hayashi, and
K Matsunaga, and
A Okahara, and
S Mita
March 1990,
Arthritis and rheumatism,
M Hayashi, and
K Matsunaga, and
A Okahara, and
S Mita
July 1993,
Agents and actions,
M Hayashi, and
K Matsunaga, and
A Okahara, and
S Mita
January 1994,
Arzneimittel-Forschung,
M Hayashi, and
K Matsunaga, and
A Okahara, and
S Mita
April 1982,
Agents and actions,
M Hayashi, and
K Matsunaga, and
A Okahara, and
S Mita
May 1984,
Archives internationales de pharmacodynamie et de therapie,
M Hayashi, and
K Matsunaga, and
A Okahara, and
S Mita
November 1990,
Agents and actions,
M Hayashi, and
K Matsunaga, and
A Okahara, and
S Mita
October 1998,
The Journal of rheumatology,
M Hayashi, and
K Matsunaga, and
A Okahara, and
S Mita
February 1986,
British journal of clinical practice. Supplement,
